Sutro Biopharma Management

Management criteria checks 3/4

Sutro Biopharma's CEO is Bill Newell, appointed in Jan 2009, has a tenure of 15.25 years. total yearly compensation is $3.04M, comprised of 21.8% salary and 78.2% bonuses, including company stock and options. directly owns 0.44% of the company’s shares, worth €1.14M. The average tenure of the management team and the board of directors is 2.1 years and 4.8 years respectively.

Key information

Bill Newell

Chief executive officer

US$3.0m

Total compensation

CEO salary percentage	21.8%
CEO tenure	15.3yrs
CEO ownership	0.4%
Management average tenure	2.1yrs
Board average tenure	4.8yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Bill Newell's remuneration changed compared to Sutro Biopharma's earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2023	n/a	n/a	-US$107m
Sep 30 2023	n/a	n/a	-US$172m
Jun 30 2023	n/a	n/a	-US$143m
Mar 31 2023	n/a	n/a	-US$130m
Dec 31 2022	US$3m	US$663k	-US$119m
Sep 30 2022	n/a	n/a	-US$123m
Jun 30 2022	n/a	n/a	-US$134m
Mar 31 2022	n/a	n/a	-US$114m
Dec 31 2021	US$6m	US$625k	-US$106m
Sep 30 2021	n/a	n/a	-US$127m
Jun 30 2021	n/a	n/a	-US$79m
Mar 31 2021	n/a	n/a	-US$43m
Dec 31 2020	US$2m	US$554k	-US$32m
Sep 30 2020	n/a	n/a	US$13m
Jun 30 2020	n/a	n/a	-US$17m
Mar 31 2020	n/a	n/a	-US$61m
Dec 31 2019	US$4m	US$497k	-US$56m
Sep 30 2019	n/a	n/a	-US$42m
Jun 30 2019	n/a	n/a	-US$40m
Mar 31 2019	n/a	n/a	-US$38m
Dec 31 2018	US$9m	US$482k	-US$35m
Sep 30 2018	n/a	n/a	-US$49m
Jun 30 2018	n/a	n/a	-US$40m
Mar 31 2018	n/a	n/a	-US$30m
Dec 31 2017	US$703k	US$468k	-US$20m

Compensation vs Market: Bill's total compensation ($USD3.04M) is above average for companies of similar size in the German market ($USD691.02K).

Compensation vs Earnings: Bill's compensation has been consistent with company performance over the past year.

CEO

Bill Newell (65 yo)

15.3yrs

Tenure

US$3,038,904

Compensation

Mr. William J. Newell, also known as Bill, J.D. has been the Chief Executive Officer and Director of Sutro Biopharma, Inc. since February 2009. He served as Independent Director at Vaxcyte, Inc. since Nove...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
William Newell	CEO & Director	15.3yrs	US$3.04m	0.44% $ 1.1m
Jane Chung	President & COO	less than a year	US$1.43m	0.055% $ 143.4k
James Swartz	Founder	no data	no data	no data
Edward Albini	CFO & Secretary	11.3yrs	US$2.08m	0.14% $ 362.7k
Venkatesh Srinivasan	Chief Technical Operations Officer	less than a year	no data	0.039% $ 102.4k
Hans-Peter Gerber	Chief Scientific Officer	less than a year	no data	no data
David Pauling	General Counsel	3.1yrs	no data	no data
Linda Fitzpatrick	Chief People & Communications Officer	16.3yrs	US$1.30m	0.11% $ 283.2k
Nicki Vasquez	Chief Portfolio Strategy & Alliance Officer	no data	no data	0.019% $ 48.5k
Anne Borgman-Hagey	Chief Medical Officer	1.2yrs	no data	0.032% $ 82.8k
Regina Cheng	Vice President & Controller	no data	no data	no data

2.1yrs

Average Tenure

60.5yo

Average Age

Experienced Management: S09's management team is considered experienced (2.1 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
William Newell	CEO & Director	15.3yrs	US$3.04m	0.44% $ 1.1m
Connie Matsui	Independent Chair of the Board	4.8yrs	US$141.51k	0% $ 0
James Panek	Independent Director	4.3yrs	US$106.51k	0% $ 0
John Freund	Independent Director	10.2yrs	US$106.51k	0.073% $ 191.4k
Daniel Petree	Independent Director	14.7yrs	US$108.51k	0.029% $ 76.3k
Trevor Hallam	Member of Scientific Advisory Board	1.3yrs	US$1.53m	0.13% $ 341.1k
Carlos Paya	Chair of the Scientific Advisory Board	3.9yrs	no data	no data
Michael Dybbs	Independent Director	5.8yrs	US$101.51k	0% $ 0
Joseph Lobacki	Independent Director	7.2yrs	US$120.51k	0% $ 0
Lawrence Fong	Co-Chair of Clinical Advisory Board & Member of Scientific Advisory Board	no data	no data	no data
Lainie Martin	Member of the Clinical Advisory Board	3.9yrs	no data	no data
Heidi Hunter	Independent Director	2.4yrs	US$111.51k	0% $ 0

4.8yrs

Average Tenure

65yo

Average Age

Experienced Board: S09's board of directors are considered experienced (4.8 years average tenure).

Sutro Biopharma Management

Management criteria checks 3/4

Key information

Recent management updates

Sutro Biopharma, Inc., Annual General Meeting, Jun 06, 2024

Sutro Biopharma, Inc Appoints Jane Chung as President and Chief Operating Officer

Sutro Biopharma, Inc. Appoints Hans Peter Gerber as Chief Scientific Officer

Chief Business Officer recently sold €67k worth of stock

Sutro Biopharma, Inc. Announces Departure of Arturo Molina as Chief Medical Officer

High number of new directors

Recent updates

Sutro Biopharma, Inc., Annual General Meeting, Jun 06, 2024

Sutro Biopharma, Inc. has completed a Follow-on Equity Offering in the amount of $74.999998 million.

Sutro Biopharma, Inc. has filed a Follow-on Equity Offering in the amount of $74.999998 million.

Full year 2023 earnings released: US$1.78 loss per share (vs US$2.35 loss in FY 2022)

Sutro Biopharma Highlights Potential Multi-Cancer Opportunity for Luvelta, a FolRa-Targeting ADC

Sutro Biopharma, Inc. Announces New Positive Data from the Compassionate Use of Luveltamab Tazevibulin (luvelta) in Pediatric Patients with Relapsed/Refractory CBF/GLIS Presented at ASH 2023

Sutro Biopharma, Inc Appoints Jane Chung as President and Chief Operating Officer

Third quarter 2023 earnings released: US$0.81 loss per share (vs US$0.37 loss in 3Q 2022)

Sutro Biopharma Announces Presentation of Data for Luveltamab Tazevibulin (luvelta) from the Phase 1 Dose-Expansion Study in Endometrial Cancers At ESMO 2023

Sutro Biopharma, Inc. Appoints Hans Peter Gerber as Chief Scientific Officer

Chief Business Officer recently sold €67k worth of stock

Second quarter 2023 earnings released: US$0.64 loss per share (vs US$0.55 loss in 2Q 2022)

First quarter 2023 earnings released: US$0.85 loss per share (vs US$0.84 loss in 1Q 2022)

Full year 2022 earnings released: US$2.35 loss per share (vs US$2.29 loss in FY 2021)

Sutro Biopharma, Inc. Announces Results from Phase 1 Dose-Expansion Study of STRO-002

Sutro Biopharma, Inc. Announces Presentation of STRO-002 Data from the Compassionate Use Program in Pediatric Patients with Relapsed/Refractory CBF/GLIS AML at ASH 2022

Third quarter 2022 earnings released: US$0.37 loss per share (vs US$0.67 loss in 3Q 2021)

Sutro Biopharma, Inc. Announces Departure of Arturo Molina as Chief Medical Officer

Second quarter 2022 earnings released: US$0.55 loss per share (vs US$0.13 loss in 2Q 2021)

High number of new directors

Sutro Biopharma, Inc.(NasdaqGM:STRO) dropped from Russell 2000 Growth Index

High number of new directors

First quarter 2022 earnings released: US$0.84 loss per share (vs US$0.66 loss in 1Q 2021)

Sutro Biopharma, Inc., Annual General Meeting, Jun 06, 2022

Sutro Biopharma, Inc. Presents Nonclinical Data for Antibody-Drug Conjugate STRO-002 at the AACR Annual Meeting 2022

CEO & Director recently bought €71k worth of stock

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Sutro Biopharma Announces Interim Data from Dose-Expansion Cohort of STRO-002 Phase 1 Study for Patients with Advanced Ovarian Cancer

High number of new directors

Sutro Biopharma, Inc. Announces Company Kol Virtual Event to Provide Interim Dose Expansion Data for Antibody-Drug Conjugate Program Stro-002 for Treatment of Advanced Ovarian Cancer

Fred Hutchinson Cancer Research Center, in Partnership with Sutro Biopharma, to Present At American Society of Hematology Annual Meeting 2021

Third quarter 2021 earnings released: US$0.67 loss per share (vs US$0.47 profit in 3Q 2020)

Second quarter 2021 earnings released: US$0.13 loss per share (vs US$1.00 profit in 2Q 2020)

Sutro Biopharma Announces Additional Data for Dose-Escalation Phase 1 Study of STRO-002 to Be Presented At ASCO 2021

Forecast to breakeven in 2025

First quarter 2021 earnings released: US$6.61 loss per share (vs US$0.84 loss in 1Q 2020)

Full year 2020 earnings released: US$0.99 loss per share (vs US$2.43 loss in FY 2019)

Investor sentiment deteriorated over the past week

Sutro Biopharma Announces First Patient Dosed in the Dose-Expansion Study of STRO-002 in Patients with Ovarian Cancer

New 90-day high: €21.00

Investor sentiment improved over the past week

Sutro Biopharma Announces Encouraging Interim Data on STRO-002 Phase 1 Dose-Escalation Study for Patients with Ovarian Cancer

Market bids up stock over the past week

New 90-day high: €18.60

Sutro Biopharma Announces Appointment of Jon M. Wigginton to Board of Directors

Sutro Biopharma, Inc. Appoints Annie Chang as Head of Investor Relations

New 90-day high: €14.30

Market bids up stock over the past week

Revenue beats expectations

Third quarter 2020 earnings released: EPS US$0.46

New 90-day high: €11.10

New 90-day high - €10.00

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age